drugset / Trial / NCT07255027

Study on the Efficacy and Safety of Anesthesia-Induced Sleep Therapy for Refractory Insomnia

NCT07255027 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

The incidence of refractory insomnia is rising annually, with traditional therapies offering limited efficacy. Anesthesia-Induced Sleep (AIS), involving anesthetic infusion like dexmedetomidine, is emerging. Its ability to mimic natural sleep architecture is unclear. Studies confirm AIS can shorten latency and improve sleep efficiency, but neuromodulatory mechanisms and long-term efficacy remain unclear with scarce follow-up data. This study used dexmedetomidine-based AIS under polysomnography to validate its induction of normal sleep architecture, evaluate long-term efficacy and safety, and explore mechanisms, aiming to provide a novel non-pharmacological intervention.

Timeline

Start
2025-12-01
Primary completion
2027-07-01
Completion
2027-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Comparator Dexmedetomidine Other / unclassified 0.7 ug/kg Intravenous

Indications